Financial Performance - In 2025, Ligand Pharmaceuticals achieved total GAAP revenue of $268 million, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [12][13] - Full-year adjusted EPS increased to $8.13, a 42% rise year-over-year, driven by strong operating leverage and higher royalty contributions [13][10] - Royalty revenue grew to $161 million, marking a 48% increase year-over-year, primarily from FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [12][5] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [13][14] - Ohtuvayre reported U.S. net sales of $506 million for the full year 2025, with Q4 sales of nearly $200 million [14] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [15] Market Data - The royalty financing market has doubled over the last five years, indicating a growing demand for royalty capital [9] - Ligand expects a compound annual growth rate of 23% in royalty receipts from 2025 through 2030, driven by contributions across its portfolio [10] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a strong emphasis on proactive portfolio management [6][19] - The company is positioned uniquely within the biopharmaceutical royalty financing sector, capitalizing on high demand for capital [9] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the royalty portfolio and the disciplined capital deployment approach, which positions the company for sustained long-term growth [11][33] - The company anticipates a strong pipeline of late-stage development programs and is optimistic about upcoming regulatory decisions and market expansions [33][27] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [17] - The company is actively engaged in monetizing older assets and exploring new investment opportunities across its portfolio [41][42] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and Lasofoxifene, with robust updates expected in the coming quarters [37] Question: Update on monetizing older assets - Management confirmed ongoing engagement with 5 to 10 opportunities for monetization and expects announcements by year-end [41] Question: Market opportunity for TZIELD - Management acknowledged the low royalty but emphasized the potential blockbuster opportunity with Sanofi's TZIELD, particularly in Stage 3 Type 1 diabetes [46] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS approval delay would have a negligible impact on the 2026 guidance, with a modest $4 million contribution assumed [51][63] Question: Differentiation of Castle Creek technology - Management discussed the potential advantages of the Castle Creek treatment over competitors, emphasizing its injectable nature and broader application [58]

Core Insights - Ligand Pharmaceuticals reported a robust financial performance with a 48% growth in royalty revenue for the full year 2025, leading to total revenues of $268.1 million, up from $167.1 million in 2024 [1][7] - The company reaffirmed its financial guidance for 2026, expecting revenues between $245 million and $285 million, with adjusted earnings per diluted share projected at $8.00 to $9.00 [1][11] Financial Performance - For Q4 2025, total revenues were $59.7 million, a 39% increase from $42.8 million in Q4 2024, primarily driven by a 45% rise in royalty revenue to $50.5 million [3][5] - Full year 2025 royalty revenues reached $161.0 million, compared to $108.8 million in 2024, attributed to increased sales of key products [7][10] - GAAP net income for Q4 2025 was $44.8 million, or $2.12 per diluted share, a significant recovery from a net loss of $31.1 million, or $1.64 per share, in Q4 2024 [5][10] Cost and Expenses - Research and development expenses for Q4 2025 were $3.5 million, down from $4.4 million in Q4 2024, while general and administrative expenses slightly decreased to $25.0 million from $25.6 million [4][9] - For the full year 2025, R&D expenses surged to $81.2 million from $21.4 million in 2024, largely due to one-time charges related to royalty financing agreements [9][10] Cash Position - As of December 31, 2025, Ligand had cash, cash equivalents, and short-term investments totaling $733.5 million, a significant increase from $256.2 million in 2024 [6][32] Business Highlights - The company highlighted the successful out-licensing and partner launch of Zelsuvmi, contributing to the strong financial results [2] - Recent product developments include positive clinical results for Filspari and Ohtuvayre, with significant sales growth reported for Filspari [12][13] Future Outlook - Ligand's 2026 financial guidance includes expected royalty revenue of $200 million to $225 million, sales of Captisol between $35 million and $40 million, and contract revenue of $10 million to $20 million [11]

Core Viewpoint - Merck Animal Health has received FDA approval for NUMELVI™, the first second-generation JAK inhibitor for treating pruritus associated with allergic dermatitis in dogs aged six months and older [1]. Company Summary - Merck Animal Health, a division of Merck & Co., Inc., is focused on developing innovative solutions for animal health [1]. - The approval of NUMELVI™ positions Merck as a leader in the veterinary pharmaceutical market, particularly in the treatment of allergic conditions in pets [1]. Industry Summary - The introduction of NUMELVI™ represents a significant advancement in the treatment options available for allergic dermatitis in dogs, addressing a common condition that affects many pets [1]. - The approval by the FDA highlights the growing regulatory support for new veterinary therapeutics, which may encourage further innovation in the animal health sector [1].

Core Viewpoint - Merck's two-drug HIV regimen has demonstrated comparable efficacy to Gilead's Biktarvy in Phase 3 trials and is currently under FDA review as the company anticipates the impact of Keytruda's patent expiration [1] Group 1: Drug Development - Merck's two-drug HIV regimen matches the performance of Gilead's Biktarvy in clinical trials [1] - The regimen is undergoing FDA review, indicating a potential for market entry [1] Group 2: Market Context - The development comes as Merck prepares for the impending patent cliff of its blockbuster drug Keytruda [1]

Core Insights - Merck announced results from three pivotal Phase 3 trials for the investigational two-drug regimen doravirine/islatravir (DOR/ISL) for HIV-1 treatment, presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) [1] Group 1: Clinical Trial Results - The Phase 3 trial MK-8591A-053 showed DOR/ISL met its primary efficacy endpoint, achieving viral suppression in 91.8% of participants compared to 90.6% for the comparator BIC/FTC/TAF, demonstrating non-inferiority [2][3] - In the MK-8591A-052 and MK-8591A-051 trials, DOR/ISL maintained high rates of viral suppression at Week 96, with similar safety profiles to BIC/FTC/TAF and baseline antiretroviral therapy [3][10] - The safety profile for DOR/ISL remained consistent, with drug-related adverse events reported in 14.1% of participants on DOR/ISL compared to 18.0% on BIC/FTC/TAF [8][11] Group 2: Regulatory and Market Implications - The U.S. FDA has set a target action date of April 28, 2026, for the New Drug Application (NDA) for DOR/ISL, which could provide a new treatment option for adults living with HIV-1 [3][10] - DOR/ISL could serve as an important alternative for patients needing adjustments in their HIV treatment regimens due to comorbidities or tolerability challenges [4] Group 3: Mechanism and Future Developments - Islatravir, the active component in DOR/ISL, blocks HIV-1 replication through multiple mechanisms, including reverse transcriptase translocation inhibition [2][15] - Merck is evaluating islatravir in various combinations for potential daily and weekly treatments for HIV-1, indicating a robust pipeline for HIV treatment options [16][17]

Product Approvals and Pipeline - The Company received significant product approvals in 2025 and early 2026, including Keytruda's approval for various cancer treatments in multiple regions, such as the FDA approval for adult patients with resectable locally advanced HNSCC in June 2025[37]. - The Company received FDA approval for the treatment of adult patients with platinum-resistant epithelial ovarian cancer in February 2026, expanding its product offerings[38]. - The FDA has committed to expediting the development and review of products with "breakthrough therapy" designation, which may accelerate market entry[77]. - The FDA review process for new drug applications typically targets a six-month review for priority reviews and ten months for standard reviews[107]. - The Company has several drug candidates in Phase 3 development, with anticipated patent expirations ranging from 2029 to 2041[95]. - The Company is diversifying its oncology portfolio with numerous Phase 3 programs focused on immuno-oncology, precision molecular targeting, and tissue targeting[127]. - The Phase 2 CADENCE trial of Winrevair met its primary endpoint, leading to plans for Phase 3 development[133]. - The Company plans to submit an NDA for MK-0616, an oral PCSK9 inhibitor, to the FDA in early 2026[131]. - MK-6482, Welireg, is being developed for expanded indications in RCC in combination with Keytruda and Lenvima[132]. - The Company has several candidates under regulatory review in the U.S. and internationally, indicating a robust pipeline[116]. - V181 is an investigational quadrivalent vaccine for dengue disease prevention, targeting all four dengue virus serotypes[134]. - MK-3000 is a potentially first-in-class tetravalent, tri-specific antibody in clinical development for diabetic macular edema[134]. - MK-8591D is an investigational once-weekly oral combination for HIV-1 treatment, currently under a partial clinical hold due to safety observations[134]. - MK-1406, a small molecule neuraminidase inhibitor, received Breakthrough Therapy designation from the FDA in 2025[134]. - Lagevrio (MK-4482) is an oral antiviral for mild to moderate COVID-19, with Emergency Use Authorization reissued in November 2023[134]. Pricing and Market Challenges - In 2025, the Company faced pricing pressure due to global health care cost containment efforts, which negatively impacted sales performance[44]. - The Company anticipates ongoing challenges from government-mandated pricing actions and cost-reduction measures affecting both generic and patented drugs[44]. - The Company entered into a three-year agreement with the U.S. government related to "most-favored-nation" drug pricing, which ties U.S. prescription drug prices to those in comparably developed nations[49]. - The competitive landscape includes pressures from generic and biosimilar competition, which may adversely affect sales of existing products[41]. - The Company expects U.S. sales of Keytruda to decline materially after government price setting becomes effective on January 1, 2029[57]. - The Company faces increasing pricing pressure due to legislative changes, including the IRA, which imposes financial penalties for drug price increases above inflation rates[57]. - The Company is subject to government-mandated annual price reductions in Japan, with the next reduction scheduled for April 2026[72]. - The new National Reimbursement Drug List (NRDL) completed recently averaged approximately 60% price reductions for new entries[73]. - Mature products entering the latest rounds of volume-based procurement (VBP) experienced an average price reduction of more than 50%[73]. - The Company anticipates ongoing pricing pressures and market access challenges in emerging markets due to government measures[74]. - Political instability, trade sanctions, and currency fluctuations may adversely impact the Company's growth in emerging markets[75]. - The EU's new pharmaceutical laws may increase pressure on pharmaceutical prices and affect the Company's market exclusivity[71]. - The Company may face greater pricing pressure from private third-party payers as the U.S. payer market consolidates[56]. - The Company expects that states will continue to exert greater influence over prescription drug pricing, including potential price control measures[60]. Research and Development - The Company is focused on research and development to maintain its competitive edge in technological innovations within the pharmaceutical industry[42]. - Approximately 24,700 employees are engaged in the Company's research and development activities as of December 31, 2025[100]. - The Company is pursuing a strong research and development program focused on breakthrough science for unmet medical needs, with a commitment to supplementing internal research through acquisitions and licensing[101]. - The clinical pipeline includes candidates across multiple disease areas, including cancer, cardiovascular diseases, and infectious diseases[102]. - The Company is currently marketing Lagevrio in the U.S. under an Emergency Use Authorization due to the COVID-19 public health crisis[110]. - The Company has a global strategic oncology collaboration with Eisai Co., Ltd. and AstraZeneca, enhancing its market position in oncology[3]. - The Company expects generic entry for certain products to be delayed until July 2030 due to ongoing litigation related to patent protections[4]. Environmental Sustainability - The company is committed to environmental sustainability, focusing on operational efficiency and minimizing environmental impact[144]. - The Company aims to reduce Scope 1 and 2 operational GHG emissions by 46% by 2030 from a 2019 baseline and has committed to a net-zero target for GHG emissions across its global operations by 2045[148]. - Expenditures for environmental remediation and liabilities were $8 million in 2025, with an estimated total of $26 million for 2026 through 2030[151]. - The Company is actively working to reduce Scope 3 emissions by 30% by 2030 from a 2019 baseline through supplier engagement initiatives[148]. - The Company has received the Peter J. Dunn Award for Green Chemistry and Engineering Impact for four of the past five years, recognizing its commitment to sustainable practices[148]. - The Company has implemented programs to divert non-hazardous landfill waste from its four highest landfill-generating sites as part of its waste diversion strategy[148]. - The Company assesses water risk throughout its network to prioritize facilities for water stewardship activities, aligning with the United Nations CEO Water Mandate[148]. - The Company does not anticipate that expenditures related to environmental initiatives will materially affect its financial condition or results of operations[150]. - The Company is exploring partnerships to advance its water stewardship priorities in the regions where it operates[149]. - The Company has established a cross-functional Environmental Sustainability Implementation Steering Committee to oversee progress on sustainability initiatives[148]. Workforce and Employment - As of December 31, 2025, the company had approximately 75,000 employees worldwide, with a voluntary turnover rate of 4.8%[138]. - In 2025, the company hired approximately 6,800 people globally through various recruitment channels[139]. - The company offers a minimum of 12 weeks of paid parental leave globally, with U.S. benefits ranking in the top quartile of Fortune's Most Admired Companies[142].

Core Viewpoint - The FDA supports mRNA vaccines but believes that U.S. taxpayers should not bear the financial burden of their development, as companies involved can fund their own research [2][8]. Group 1: FDA's Position on mRNA Vaccines - FDA Commissioner Marty Makary defended the agency's stance on mRNA vaccines, stating that the FDA has approved two mRNA vaccines for RSV [3]. - The FDA is reviewing a Moderna flu vaccine, indicating ongoing support for mRNA technology [1][2]. Group 2: Funding Decisions and Rationale - The U.S. Department of Health and Human Services (HHS) cut funding for mRNA vaccine research, with Makary explaining that companies like Moderna and Pfizer, which made over $50 billion, can afford their own research [5][8]. - The HHS's decision to defund mRNA vaccine development was influenced by a belief that the vaccines were not effectively protecting against respiratory infections, despite contrary scientific evidence [5][6]. Group 3: Future Research Directions - Makary emphasized the need for government funding to focus on underfunded areas such as rare diseases and bespoke conditions, rather than mRNA vaccine research [9].

Core Insights - Merck is restructuring its human-health operations into two divisions: oncology and specialty, to better prepare for the impending patent loss of Keytruda in 2028, which currently accounts for nearly half of the company's sales [1][1][1] Group 1: Business Reorganization - The oncology division will focus on Keytruda and other cancer therapies, while the specialty division will manage non-cancer products, including established drugs like Gardasil and Januvia, as well as newer therapies like Winrevair [1][1] - Leadership changes include Brian Foard as president of the specialty division and Jannie Oosthuizen as head of the oncology division, both reporting to CEO Robert Davis [1][1][1] Group 2: Strategic Focus and Growth - Merck aims to launch over 20 new drugs or expanded uses for existing products in the coming years, including a new cholesterol pill expected to contribute significantly to revenue [1][1] - The company has estimated that its current pipeline could generate over $70 billion in potential commercial opportunities by the mid-2030s, more than double previous peak sales estimates for Keytruda [1][1][1] Group 3: Financial Performance and Market Position - Merck reported better-than-expected fourth-quarter 2025 results, surpassing analysts' forecasts for both revenue and earnings, which has bolstered investor confidence despite the challenges posed by Keytruda's patent expiration [1][1] - The company's phase III pipeline has nearly tripled since 2021, supported by internal research and acquisitions, including the notable purchase of Verona, which introduced a new therapy for chronic obstructive pulmonary disease [1][1][1]

Core Insights - Brown Capital Management's Small Company Fund underperformed in Q4 2025, with a decline of 1.50% compared to the Russell 2000® Growth index's gain of 1.22% [1] - The Fund's performance for the entire year of 2025 was down 11.46%, significantly lagging behind the Index's return of 13.01% [1] - The Fund's investment strategy is based on company fundamentals, which showed strong revenue and earnings growth in 2025 [1] Company Focus: Veeva Systems Inc. - Veeva Systems Inc. (NYSE:VEEV) is a technology company providing a cloud-based software platform for the life sciences industry, with a market capitalization of $29.64 billion [2] - The stock of Veeva Systems Inc. experienced a one-month return of -19.57% and a 52-week decline of 20.26% [2] - Veeva Systems was identified as a detractor from the Fund's performance in Q4 2025, despite its strong market position and innovative solutions in the life sciences sector [3] - The company's offerings include Veeva Customer Relationship Management (CRM) and Veeva Vault, which have established a dominant market position and present opportunities for growth in clinical applications [3] - Veeva's client base includes major global pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Eli Lilly, Merck, and Novartis [3]

Company Overview - Proactive is a financial news and online broadcast organization that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates across six offices on three continents, including key financial hubs such as London, New York, Toronto, Vancouver, Sydney, and Perth [2] Content Production - Proactive's editorial team produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - The content covers a wide range of topics, including medium and small-cap markets, blue-chip companies, commodities, biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]